A Return from Botox to Botulism

Topics: Botulism, Botulinum toxin, Clostridium botulinum Pages: 7 (2168 words) Published: October 4, 2014

A Return from BOTOX to Botulism

By: T. Claire Frances
Date: July 10, 2014
Instructor: Linda Maywood, MSN, CPNP
Course Title: HIT 102 Pharmacology of Allied Health Professions


BOTOX, Dysport, Xeomin (onabotulinumtoxinA, BTX-A); BTX-B (Myobloc), BTX, BoNT, BTX A-G, C. Botulinum, botulinum toxin; and since 2013, BTX-H; These are all terms synonymous or derived from the most dangerous toxin known to humankind, Botulism. Botulism is the term used most often to describe the serotypes derived from Clostridium botulinum. C. botulinum it's purported, was first isolated as a bacterium by Belgium bacteriologist Emile Pierre van Ermengem in 1897. Botulism (Latin, botulus, meaning "sausage") was prior to coined by poet and physician Justinus Kerner who discovered the "sausage poison;" and who first theorized future therapeutic benefits of the toxic. (Kedlaya,2014).

BTX is found in the soil and survives in low oxygen environments; also found in animals as well as humans. Until 2013, the most potent form of BTX toxic was Botulism Type A. Type A and Type B are approved by the Food and Drug Administration (FDA) for cosmetic procedures; however, it does not pose the same risks as food-borne BTX. Controlled doses for therapeutic medicine are purified and diluted for aesthetic medicine, marketed as BOTOX. Up until 2013, seven major types of BTX were universally accepted serotypes, designated A through G, of which only A, B, E and F cause illness in humans. (Davis, 2014)

The growing popularity of Botulinum toxin, BTX-A is evident with common cosmetic procedure reportedly doubled up to 6.1 million procedures (up 8%) in 2012 according to the American Society of Plastic Surgeons (ASPS) (Reath, 2013). The FDA has approved BTX-A and BTX-B for cosmetic purposes. Although medical risks are much decreased with diluted forms of the neurotoxin, there are many side effects; even before any severe but rare incidence of BTX's spread to other parts of body. If injections aren't correctly placed, the BTX may spread into adjacent tissues producing symptoms such as eyelid droop, cockeyed eyebrows, crooked smile, dry eye or excessive tearing. (Mayo, 2013).

Botox is marketed in the United States by Allergan, Inc. Allergan's provides a 36 page safety sheet outlining the multitudinous side effects for the FDA approved uses of BTX-A, under brand names Dysport and Xeomin; and Type B, brand name Myobloc. Type A toxin was initially developed outside the U.S. (Europe, China, Germany and elsewhere); and type B, within the U.S. Therapeutic uses are extensive, ranging from eye treatments both cosmetic and corrective, to muscle injections for migraines and Cervical Dystonia. (Allergan, 2014)

Publications referencing the therapeutic efficacy of Botulinum toxin for medical purposes was by an ophthalmologist in 1980, Dr. Alan B. Scott, MD, for treatment of strabismus (cross eyes) in patients having researched BTX since the 1960s. (Felber). Botulinum toxin products have also been approved by FDA for one or more of the following uses: temporary improved appearance of glabellar lines (frown lines, eyebrows), strabismus, blepharospasm (abnormal eyelid tics and twitches), cervical dystonia (involuntary sustained or repetitive neck muscles contractions), and primary axillary hyperhidrosis (severe underarm sweating). For these uses, botulinum toxin is injected into the skin or muscle tissue. However, in a postmarketing review from 2009, the FDA reaffirmed its 2008 decision not to approve BTX for cerebral palsy, citing the possible side effect risks indicated plus, "Serious case reports described hospitalizations involving ventilatory support and reports of death." (FDA, 2009)

Cosmetic Botox is a heavily diluted and purified form of Clostridium botulinum and only available by prescription. It's administered to patients via injection; dispensed in a powder form in units of 50,100, or 200. BOTOX is reconstituted with sterile, non-preserved 0.9%...

Cited: "Botox (Botulinum Toxin Type A) Drug Information: Indications, Dosage and How Supplied." RxList.com. RxList, 2014. Web. 08 July 2014. .
"Botox Injections." Tests and Procedures Botox Injections: Risks. Mayo Clinic, 6 Feb. 2013. Web. 05 July 2014. .
"Botulism." Centers for Disease Control and Prevention. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), 25 Apr. 2014. Web. 03 July 2014.
"Botulism Fact Sheet N°270." WHO. World Health Organization, 2013. Web. 06 July 2014. .
"Botulism General Information." Centers for Disease Control and Prevention. Centers for Disease Control and Prevention, 25 Apr. 2014. Web. 06 July 2014. .
Davis, Charles P., M.D., Ph.D. "Botulism Symptoms, Causes, Treatment - How Does Botulism Neurotoxin Affect the Body? - MedicineNet." MedicineNet. Ed. Melissa C. Stoppler, M.D. MedicineNet.com, 2014. Web. 09 July 2014. .
"Generic Name: Botulism Immune Globulin (Pronunciation: BOT Ue Lizm Im MYOON GLOB Yoo Lin)." EMedicineHealth. WebMD, 2014. Web. 07 July 2014. .
Allergan. "HIGHLIGHTS OF PRESCRIBING INFORMATION." BOTOX® Prescribing Information (2013): 1-36. Allergan.com. Allergan, Aug. 2013. Web. 4 June 2013. .
Kedlaya,, Divakara, MBBS. "Botulinum Toxin ." Botulinum Toxin. Ed. Francisco Talavera, PharmD, PhD and Consuelo T. Lorenzo, , MD. MedScape, 7 Feb. 2014. Web. 06 July 2014. .
"Medications and Drugs Brand Names: BabyBIG." Emedicinehealth.com. Cerner Multum, Inc., 15 Dec. 2010. Web. 05 July 2014. .
Ogbru, Omudhome, PharmD. "OnabotulinumtoxinA, Botox, Botox Cosmetic: Drug Facts, Side Effects and Dosing." Botulinum Toxin - Injection, Botox, Botox Cosmetic, Dysport. Ed. Jay W. Marks, MD. MedicineNet, 2014. Web. 05 July 2014. .
Reath, David, MD. "14.6 Million Cosmetic Plastic Surgery Procedures Performed in 2012." 14.6 Million Cosmetic Plastic Surgery Procedures Performed in 2012. American Society of Plastic Surgeons, 19 Feb. 2013. Web. 06 July 2014. .
Ventura, Jeffrey. "FDA Approves Botox to Treat Specific Form of Urinary Incontinence." FDA Approves Botox to Treat Specific Form of Urinary Incontinence. U.S. Food and Drug Administration, 25 Aug. 2011. Web. 06 July 2014. .
Weller, Chris. "Botulinum Toxin Deemed Deadliest Substance Ever: Sniffing 13-Billionths Of A Gram Can Kill." New Botulinum Toxin Deemed Deadliest Substance Ever: Sniffing 13-Billionths Of A Gram Can Kill. Medical Daily, 15 Oct. 2013. Web. 06 July 2014. .
"What Is BabyBIG." Infantbotulism.org. California Department of Public Health, 2010. Web. 03 July 2014. .
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • Botulism Essay
  • Botulism Research Paper
  • Essay on Botox
  • Essay about Botox
  • Botulism Research Paper
  • Botulism Essay
  • Botulism: Benefits and Side Effects Essay
  • Botulism- Case Study Essay

Become a StudyMode Member

Sign Up - It's Free